Skip to Main Content

Paper Details

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer
2
2023
ATM, ATR, BRCA1/2, CHK1, DNA, DNA polymerase theta, DNA topoisomerase I, DNA-PK, Ewing sarcoma, PARP, PARP1, PKMYT1, WEE1, adult cancers, cancer, childhood tumours, children, desmoplastic small round cell tumours, homologous recombination-deficient tumours, neuroblastoma, paediatric cancers, paediatric malignancies, patient, patients
Author NameAffiliation
Elizabeth StewartSt Jude Children's Research Hospital
Elizabeth StewartSt Jude Children's Research Hospital
Malcolm A SmithNational Cancer Institute
Malcolm A SmithNational Cancer Institute
Gregory H Reaman
Gregory H Reaman
Alberto S PappoSt Jude Children's Research Hospital
Lynley V MarshallThe Royal Marsden NHS Foundation Hospital, The Institute of Cancer Research
Marcel KoolHopp Children's Cancer Center
Marcel KoolHopp Children's Cancer Center
Anton G Henssen
Douglas S HawkinsSeattle Children's Hospital
Barry R Davies
Gilles VassalBelgium Gustave Roussy Cancer Centre
  • 1 - 14

Datasets

Release 1.2